AU4347696A - Use of mhc-ii binding and/or mhc-ii mimicking molecules for the prevention and/or treatment of inflammatory diseases - Google Patents

Use of mhc-ii binding and/or mhc-ii mimicking molecules for the prevention and/or treatment of inflammatory diseases

Info

Publication number
AU4347696A
AU4347696A AU43476/96A AU4347696A AU4347696A AU 4347696 A AU4347696 A AU 4347696A AU 43476/96 A AU43476/96 A AU 43476/96A AU 4347696 A AU4347696 A AU 4347696A AU 4347696 A AU4347696 A AU 4347696A
Authority
AU
Australia
Prior art keywords
mhc
prevention
binding
treatment
inflammatory diseases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU43476/96A
Inventor
Roger Pascal Lauener
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
DEUTSCHE OM ARZNEIMITTEL GmbH
Laboratoires OM SA
Original Assignee
DEUTSCHE OM ARZNEIMITTEL GmbH
OM LAB SA
Laboratoires OM SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by DEUTSCHE OM ARZNEIMITTEL GmbH, OM LAB SA, Laboratoires OM SA filed Critical DEUTSCHE OM ARZNEIMITTEL GmbH
Publication of AU4347696A publication Critical patent/AU4347696A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
AU43476/96A 1994-12-23 1995-12-27 Use of mhc-ii binding and/or mhc-ii mimicking molecules for the prevention and/or treatment of inflammatory diseases Abandoned AU4347696A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP94203755 1994-12-23
EP94203755 1994-12-23
PCT/EP1995/005164 WO1996020215A2 (en) 1994-12-23 1995-12-27 Use of mhc-ii binding and/or mhc-ii mimicking molecules for the prevention and/or treatment of inflammatory diseases

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU63167/99A Division AU6316799A (en) 1994-12-23 1999-12-06 Use of MCH-II binding and/or MHC-II mimicking molecules for the prevention and/or treatment of inflammatory diseases

Publications (1)

Publication Number Publication Date
AU4347696A true AU4347696A (en) 1996-07-19

Family

ID=8217495

Family Applications (1)

Application Number Title Priority Date Filing Date
AU43476/96A Abandoned AU4347696A (en) 1994-12-23 1995-12-27 Use of mhc-ii binding and/or mhc-ii mimicking molecules for the prevention and/or treatment of inflammatory diseases

Country Status (11)

Country Link
EP (1) EP0800534A2 (en)
JP (1) JPH10511652A (en)
CN (1) CN1171117A (en)
AU (1) AU4347696A (en)
BR (1) BR9510554A (en)
CA (1) CA2208233A1 (en)
CZ (1) CZ186897A3 (en)
HU (1) HUT77468A (en)
PL (1) PL320922A1 (en)
SK (1) SK80697A3 (en)
WO (1) WO1996020215A2 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5840835A (en) * 1995-10-30 1998-11-24 Merck & Co., Inc. Inhibitors of peptide binding to MHC class II proteins
US5817757A (en) * 1995-10-30 1998-10-06 Merck & Co., Inc. Inhibitors of peptide binding to MHO class II proteins
US5719296A (en) * 1995-10-30 1998-02-17 Merck & Co., Inc. Pseudopeptide lactam inhibitors of peptide binding to MHC class II proteins
EP0889964A1 (en) 1996-03-28 1999-01-13 The Johns Hopkins University Soluble divalent and multivalent heterodimeric analogs of proteins
US6458354B1 (en) 1996-03-28 2002-10-01 The Johns Hopkins University Molecular complexes which modify immune responses
US6268411B1 (en) 1997-09-11 2001-07-31 The Johns Hopkins University Use of multivalent chimeric peptide-loaded, MHC/ig molecules to detect, activate or suppress antigen-specific T cell-dependent immune responses
EP0893507A1 (en) * 1997-07-25 1999-01-27 Institut Gustave Roussy Use of MHC class II ligands (CD4 and LAG-3) as adjuvant for vaccination and of LAG-3 in cancer treatment
GB0201896D0 (en) * 2002-01-28 2002-03-13 Ice Biolog Ltd Treatment
HU228957B1 (en) * 2001-07-02 2013-07-29 Aimsco Ltd Use anti-hla-antibody for production of pharmaceutical compotisions for the treatment of diseases involving prolierative immune response
CA2473754C (en) * 2002-01-28 2012-04-10 Aimsco Limited Treatment of ms with goat serum
ES2232273B1 (en) * 2003-03-21 2006-07-16 Jose Manuel Fernandez-Real Lemos NEW THERAPEUTIC APPLICATIONS OF GLUCOPROTEIN CD14S.
EP2266606B1 (en) * 2003-05-15 2014-09-10 Genentech, Inc. Methods and compositions for the prevention and treatment of sepsis

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3269354D1 (en) * 1981-06-25 1986-04-03 Univ Leland Stanford Junior Allele specific immunotherapeutic method and dosage form
GB8310403D0 (en) * 1983-04-18 1983-05-25 Mach B F Cotransformed mouse cells
EP0204522A3 (en) * 1985-05-30 1987-09-16 Genetic Systems Corporation Monoclonal antibody panel for histocompatibility typing
JPS63275526A (en) * 1987-05-03 1988-11-14 Hiroshi Okajima Hiv virus neutralizing antibody
FR2658197B1 (en) * 1990-02-14 1992-05-22 Inst Nat Sante Rech Med RESTRICTED MONOCLONAL ANTIBODIES RECOGNIZING A PEPTIDE ASSOCIATED WITH A MAJOR HISTOCOMPATIBILITY COMPLEX ANTIGEN - APPLICATIONS TO DIAGNOSIS AND TREATMENT.
DE4029227A1 (en) * 1990-09-14 1992-03-19 Imtox Gmbh MEDICINAL PRODUCT CONTAINING CD14
AU3220593A (en) * 1991-11-19 1993-06-15 Anergen, Inc. Soluble mhc molecules and their uses
EP0634935A4 (en) * 1992-04-06 1996-01-31 North Shore Univ Hospital A novel therapy for treating sepsis using a soluble form of recombinant cd14 myelomonocytic antigen.
ATE223485T1 (en) * 1992-10-15 2002-09-15 Toray Industries METHOD FOR PRODUCING RECOMBINANT MHCII PROTEIN IN MICROORGANISMS
EP0751962B1 (en) * 1993-05-28 2006-08-02 The Scripps Research Institute Methods for inhibiting cd14 mediated cell activation
US6180377B1 (en) * 1993-06-16 2001-01-30 Celltech Therapeutics Limited Humanized antibodies

Also Published As

Publication number Publication date
PL320922A1 (en) 1997-11-10
SK80697A3 (en) 1997-12-10
JPH10511652A (en) 1998-11-10
CN1171117A (en) 1998-01-21
HUT77468A (en) 1998-05-28
CA2208233A1 (en) 1996-07-04
BR9510554A (en) 1999-06-29
CZ186897A3 (en) 1998-03-18
WO1996020215A2 (en) 1996-07-04
EP0800534A2 (en) 1997-10-15
WO1996020215A3 (en) 1996-10-10

Similar Documents

Publication Publication Date Title
AU4172597A (en) Polydithiocarbamate-containing macromolecules and the use thereof for therapeutic and diagnostic applications
AU2103097A (en) Cinnoline derivatives and use as medicine
AU3897897A (en) Methods and apparatus for the application of combined fields to disinfect fluids
HUP9904361A3 (en) Use of isobutylgaba and its derivatives for the treatment of pain
AU6974996A (en) Compositions for the treatment of dermatological disorders and methods for their use
AU3793697A (en) Apparatus and methods for the disinfection of fluids
AU9403798A (en) Human regulatory molecules
AU4180596A (en) Functionalised polyorganosiloxanes and one of the processes for the preparation thereof
AU3666695A (en) Pyridazinones and their use as fungicides
AU5563398A (en) Use of mifepristone for the treatment of psychoses and addictive behaviours
AU4347696A (en) Use of mhc-ii binding and/or mhc-ii mimicking molecules for the prevention and/or treatment of inflammatory diseases
AU2387097A (en) Substituted benzylamines and their use for the treatment of depression
AU2821295A (en) Compositions and methods for the treatment of tumors
AU1556497A (en) Agents for the treatment and prevention of aids
AU7448198A (en) Compositions and means for the treatment of burns and other cutaneous traumas
AU5537296A (en) The use of cross-linked hemoglobin in treating subarachnoid hemorrhage
AU6177994A (en) System for the protection of people and/or property
ZA958558B (en) Use of inhibitors of cyclooxygenase in the treatment of neurodegenerative diseases
AU2154695A (en) Thioprostaglandins and -prostaglandin-like compounds and therapeutic uses thereof
AU2705495A (en) Use of rooperol and hypoxoside and their derivatives in the treatment of inflammatory
AUPM885894A0 (en) Therapeutic molecules
AU8049098A (en) Composition and methods for the treatment of inflammatory diseases
AU7161096A (en) Compositions and methods for inhibiting the binding of pecam
EP0893123A4 (en) Agent for use in the prevention and treatment of disorders associated with various types of ageing
AU1587295A (en) The treatment of gaseous substances

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted